NCT06282549

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension

A Prospective Long-term Cohort Study to Identify the Predictive Model of Cardiocerebrovascular Risk Factors in Elderly Patients with More Than Three Antihypertensive Agents in Patients with Essential Hypertension in Korea

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,219 (actual)
• Sponsor: Yuhan Corporation · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination.

Detailed description

This is a phase IV, open-label, prospective, long-term cohort, observational study to identify the predictive model of cardiocerebrovascular risk factors in elderly patients with more than three antihypertensive agents in patients with essential hypertension in Korea.

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	Telmisartan/Amlodipine/Chlorthalidone(Truset)	Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/25 mg

Timeline

• Start date: 2022-06-08
• Primary completion: 2027-03-31
• Completion: 2027-03-31
• First posted: 2024-02-28
• Last updated: 2024-11-19

Locations

5 sites across 1 country: South Korea